The assay of a novel histamine H2-receptor antagonist, SK&F 93479, in human plasma by normal-phase high-performance liquid chromatography.
A selective assay of a new histamine H2-receptor antagonist, SK&F 93479, in human plasma has been developed. The method uses liquid-liquid extraction from the biological sample and analysis of the resulting extract by normal-phase high-performance liquid chromatography with UV detection for quantitation of the drug and an added standard. The assay is sufficiently accurate and precise to determine the compound at concentrations as low as 0.025 mg 1(-1). The coefficient of variation of the assay averages 5.7% at concentrations between 0.1 and 2.0 mg 1(-1), but increases to 21.8% at 0.02 mg 1(-1). SK&F 93479 can be determined in spiked plasma samples, at concentrations between 0.05 and 0.80 mg 1(-1) with a bias of between -7.5 and +3.6%, but at 0.02 mg 1(-1) concentrations were underestimated by 15% on average. The assay has been used for pharmacokinetic and bioavailability studies: after a single 0.5 mg kg-1 oral dose in man, plasma concentrations can be monitored for up to 70 h after dosing.
D002851:Chromatography, High Pressure Liquid; D006635:Histamine H2 Antagonists / Q000097:blood; D006801:Humans; D007700:Kinetics; D008297:Male; D011744:Pyrimidinones / Q000097:blood* / Q000302:isolation & purification; D013048:Specimen Handling
D006635:Histamine H2 Antagonists; D011744:Pyrimidinones; C033275:SK&F 93479